The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 25, 2017

Filed:

Jan. 28, 2016
Applicant:

Massachusetts Institute of Technology, Cambridge, MA (US);

Inventors:

John M. Essigmann, Cambridge, MA (US);

Andrei Tokmakoff, Evanston, IL (US);

Bogdan I. Fedeles, Cambridge, MA (US);

Vipender Singh, Cambridge, MA (US);

Chunte Peng, Mountain View, CA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01N 43/04 (2006.01); A61K 31/70 (2006.01); C07H 19/12 (2006.01); A61K 31/7052 (2006.01); A61K 31/706 (2006.01); A61K 31/7076 (2006.01); A61K 31/708 (2006.01); C07H 19/04 (2006.01); C07H 19/173 (2006.01); C07H 19/23 (2006.01); C12Q 1/68 (2006.01); G01N 21/3577 (2014.01); G01N 33/15 (2006.01); A61K 31/7068 (2006.01); A61K 31/7064 (2006.01);
U.S. Cl.
CPC ...
C07H 19/12 (2013.01); A61K 31/706 (2013.01); A61K 31/708 (2013.01); A61K 31/7052 (2013.01); A61K 31/7076 (2013.01); C07H 19/04 (2013.01); C07H 19/173 (2013.01); C07H 19/23 (2013.01); C12Q 1/6811 (2013.01); G01N 21/3577 (2013.01); G01N 33/15 (2013.01); A61K 31/7064 (2013.01); A61K 31/7068 (2013.01);
Abstract

The present disclosure provides nucleoside analogs of Formula (I) or (II). The nucleoside analogs are expected to show multiple tautomerism and may increase the mutation of an RNA and/or DNA (be mutagenic) of a virus or cancer cell. The multiple tautomerism and mutagenesis of the nucleoside analogs may be adjusted by substituting the nucleoside analogs with one or more electron-donating groups and/or electron-withdrawing groups to increase or decrease the pK(e.g., to a pKbetween 5.5 or 8.5). The present disclosure also provides pharmaceutical compositions and kits including the nucleoside analogs and methods of treating a viral infection (e.g., influenza, HIV infection, or hepatitis) or cancer using the nucleoside analogs, pharmaceutical compositions, or kits.


Find Patent Forward Citations

Loading…